Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Large Drop in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 80,592 shares, a decline of 43.7% from the June 30th total of 143,052 shares. Currently, 6.8% of the shares of the company are short sold. Based on an average daily trading volume, of 183,392 shares, the days-to-cover ratio is presently 0.4 days.

Regentis Biomaterials Stock Performance

NYSEAMERICAN:RGNT traded up $0.02 during mid-day trading on Thursday, hitting $1.80. 68,144 shares of the company traded hands, compared to its average volume of 2,417,372. The company has a fifty day moving average of $2.95. Regentis Biomaterials has a one year low of $1.23 and a one year high of $15.50.

Institutional Trading of Regentis Biomaterials

A hedge fund recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.